{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:00:19Z","timestamp":1791018019294,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T00:00:00Z","timestamp":1181001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T00:00:00Z","timestamp":1181001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1038\/sj.tpj.6500463","type":"journal-article","created":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T10:20:39Z","timestamp":1181643639000},"page":"278-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy"],"prefix":"10.1038","volume":"8","author":[{"given":"A","family":"Ruzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Loupakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Bisonni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Ficarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Canestrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Pizzagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Alessandroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Giustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Maltese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E T","family":"Menichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,5]]},"reference":[{"key":"BF6500463_CR1","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1200\/JCO.2005.17.749","volume":"23","author":"H Kelly","year":"2005","unstructured":"Kelly H, Goldberg RM . Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553\u20134560.","journal-title":"J Clin Oncol"},{"key":"BF6500463_CR2","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","volume":"23","author":"G Colucci","year":"2005","unstructured":"Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866\u20134875.","journal-title":"J Clin Oncol"},{"key":"BF6500463_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/sj.bjc.6601487","volume":"90","author":"S Marsh","year":"2004","unstructured":"Marsh S, McLeod HL . Cancer pharmacogenetics. Br J Cancer 2004; 90: 8\u201311.","journal-title":"Br J Cancer"},{"key":"BF6500463_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1517\/14622416.5.7.835","volume":"5","author":"S Marsh","year":"2004","unstructured":"Marsh S, McLeod HL . Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004; 5: 835\u2013843.","journal-title":"Pharmacogenomics"},{"key":"BF6500463_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1200\/JCO.2004.05.064","volume":"22","author":"S Popat","year":"2004","unstructured":"Popat S, Matakidou A, Houlston RS . Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529\u2013536.","journal-title":"J Clin Oncol"},{"key":"BF6500463_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1247\/csf.20.191","volume":"20","author":"N Horie","year":"1995","unstructured":"Horie N, Aiba H, Oguro K, Hojo H, Takeishi K . Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5\u2032-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191\u2013197.","journal-title":"Cell Struct Funct"},{"key":"BF6500463_CR7","first-page":"6004","volume":"63","author":"K Kawakami","year":"2003","unstructured":"Kawakami K, Watanabe G . Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of the thymidylate synthase gene. Cancer Res 2003; 63: 6004\u20136007.","journal-title":"Cancer Res"},{"key":"BF6500463_CR8","first-page":"2898","volume":"63","author":"MV Mandola","year":"2003","unstructured":"Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ et al. A novel single nucleotide polymorphism within the 5\u2032 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898\u20132904.","journal-title":"Cancer Res"},{"key":"BF6500463_CR9","first-page":"3249","volume":"19","author":"K Kawakami","year":"1999","unstructured":"Kawakami K, Omura K, Kanehira E, Watanabe Y . Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999; 19: 3249\u20133252.","journal-title":"Anticancer Res"},{"key":"BF6500463_CR10","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.ejca.2005.06.016","volume":"41","author":"M Morganti","year":"2005","unstructured":"Morganti M, Ciantelli M, Giglioni B, Putignano AL, Nobili S, Papi L et al. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 2005; 41: 2176\u20132183.","journal-title":"Eur J Cancer"},{"key":"BF6500463_CR11","first-page":"484","volume":"45","author":"K Kawakami","year":"2004","unstructured":"Kawakami K, Watanabe G . The association of thymidylate synthase mRNA expression with its three gene polymorphisms in colorectal cancer. Proc Am Assoc Cancer Res 2004; 45: 484 (abstr 2104).","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF6500463_CR12","first-page":"1381","volume":"9","author":"CM Ulrich","year":"2000","unstructured":"Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD . Searching expressed sequence Tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000; 9: 1381\u20131385.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BF6500463_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00008571-200405000-00007","volume":"14","author":"MV Mandola","year":"2004","unstructured":"Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004; 14: 319\u2013327.","journal-title":"Pharmacogenetics"},{"key":"BF6500463_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/jnci\/djh015","volume":"96","author":"KJ Sohn","year":"2004","unstructured":"Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI . Effect of the methylenetetrahydrofolate reductase C677\u2009T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96: 134\u2013144.","journal-title":"J Natl Cancer Inst"},{"key":"BF6500463_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/sj.bjc.6601523","volume":"90","author":"MC Etienne","year":"2004","unstructured":"Etienne MC, Ilc K, Formento JL, Laurent-Puig P, Formento P, Cheradame S et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br J Cancer 2004; 90: 526\u2013534.","journal-title":"Br J Cancer"},{"key":"BF6500463_CR16","first-page":"5860","volume":"9","author":"K Kawakami","year":"2003","unstructured":"Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Watanabe G, Iacopetta B . The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 2003; 9: 5860\u20135865.","journal-title":"Clin Cancer Res"},{"key":"BF6500463_CR17","first-page":"4519","volume":"62","author":"MF Paz","year":"2002","unstructured":"Paz MF, Avila S, Fraga MF, Pollan M, Capella G, Peinado MA et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002; 62: 4519\u20134524.","journal-title":"Cancer Res"},{"key":"BF6500463_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevOncog.v12.i1-2.60","volume":"12","author":"B Iacopetta","year":"2006","unstructured":"Iacopetta B . Methyl-group metabolism and the response of colorectal cancer to 5-Fluorouracil. Crit Rev Oncogenesis 2006; 12: 1\u201312.","journal-title":"Crit Rev Oncogenesis"},{"key":"BF6500463_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Y Pommier","year":"2006","unstructured":"Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006; 6: 789\u2013802.","journal-title":"Nat Rev Cancer"},{"key":"BF6500463_CR20","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921\u20136926.","journal-title":"Cancer Res"},{"key":"BF6500463_CR21","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1158\/1078-0432.CCR-03-0548","volume":"10","author":"E Rouits","year":"2004","unstructured":"Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E . Relevance of different UGT1A1 toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151\u20135159.","journal-title":"Clin Cancer Res"},{"key":"BF6500463_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","volume":"91","author":"E Marcuello","year":"2004","unstructured":"Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M . UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678\u2013682.","journal-title":"Br J Cancer"},{"key":"BF6500463_CR23","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2005.05.5400","volume":"24","author":"G Toffoli","year":"2006","unstructured":"Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061\u20133068.","journal-title":"J Clin Oncol"},{"key":"BF6500463_CR24","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K . Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187\u20134191.","journal-title":"Cancer Res"},{"key":"BF6500463_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1124\/mol.61.4.742","volume":"61","author":"J Wu","year":"2002","unstructured":"Wu J, Yin MB, Hapke G, Toth K, Rustum YM . Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol Pharmacol 2002; 61: 742\u2013748.","journal-title":"Mol Pharmacol"},{"key":"BF6500463_CR26","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/ijc.22129","volume":"119","author":"D Vallbohmer","year":"2006","unstructured":"Vallbohmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M et al. Molecular determinants of irinotecan efficacy. Int J Cancer 2006; 119: 2435\u20132442.","journal-title":"Int J Cancer"},{"key":"BF6500463_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0027-5107(02)00217-8","volume":"509","author":"JG de Boer","year":"2002","unstructured":"de Boer JG . Polymorphisms in DNA repair and environmental interactions. Mutat Res 2002; 509: 201\u2013210.","journal-title":"Mutat Res"},{"key":"BF6500463_CR28","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J","volume":"91","author":"C Louvet","year":"2001","unstructured":"Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M . Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001; 91: 2033\u20132038.","journal-title":"Cancer"},{"key":"BF6500463_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"key":"BF6500463_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/sj.tpj.6500012","volume":"1","author":"ST Pullarkat","year":"2001","unstructured":"Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenom J 2001; 1: 65\u201370.","journal-title":"Pharmacogenom J"},{"key":"BF6500463_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.bjc.6601975","volume":"91","author":"J Stoehlmacher","year":"2004","unstructured":"Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU\/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344\u2013354.","journal-title":"Br J Cancer"},{"key":"BF6500463_CR32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2005.03.5253","volume":"24","author":"E Dotor","year":"2006","unstructured":"Dotor E, Cuatrecases M, Martinez-Iniesta M, Navarro M, Vilardell F, Guino E et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24: 1603\u20131611.","journal-title":"J Clin Oncol"},{"key":"BF6500463_CR33","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1200\/JCO.2005.06.219","volume":"23","author":"A Jakobsen","year":"2005","unstructured":"Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J . Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365\u20131369.","journal-title":"J Clin Oncol"},{"key":"BF6500463_CR34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ijc.20487","volume":"112","author":"E Marcuello","year":"2004","unstructured":"Marcuello E, Altes A, del Rio E, Cesar A, Menoyo A, Baiget M . Single nucleotide polymorphism in the 5\u2032 tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004; 112: 733\u2013737.","journal-title":"Int J Cancer"},{"key":"BF6500463_CR35","first-page":"1611","volume":"9","author":"V Cohen","year":"2003","unstructured":"Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R . Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611\u20131615.","journal-title":"Clin Cancer Res"},{"key":"BF6500463_CR36","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/00008571-200412000-00001","volume":"14","author":"MC Etienne","year":"2004","unstructured":"Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14: 785\u2013792.","journal-title":"Pharmacogenetics"},{"key":"BF6500463_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00280-005-0089-1","volume":"57","author":"E Marcuello","year":"2006","unstructured":"Marcuello E, Altes A, Menoyo A, Baiget M . Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2006; 57: 835\u2013840.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6500463_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00439-004-1243-2","volume":"1160","author":"C Kealey","year":"2005","unstructured":"Kealey C, Brown KS, Woodside JV, Young I, Murray L, Boreham CA et al. A common insertion\/deletion polymorphism of the thymidylate synthase (TYMS) gene is a determinant of red blood cell folate and homocysteine concentrations. Hum Genet 2005; 1160: 347\u2013353.","journal-title":"Hum Genet"},{"key":"BF6500463_CR39","doi-asserted-by":"publisher","first-page":"23456","DOI":"10.1074\/jbc.M600282200","volume":"281","author":"R Pullmann Jr","year":"2006","unstructured":"Pullmann Jr R, Abdelmohsen K, Lal A, Martindale JL, Ladner RD, Gorospe M . Differential stability of thymidylate synthase 3\u2032-untranslated region polymorphic variants regulated by AUF1. J Biol Chem 2006; 281: 23456\u201323463.","journal-title":"J Biol Chem"},{"key":"BF6500463_CR40","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382\u20131388.","journal-title":"J Clin Oncol"},{"key":"BF6500463_CR41","first-page":"151","volume":"24","author":"HL McLeod","year":"2006","unstructured":"McLeod HL, Parodi L, Sargent DJ, Marsh S, Green E, Abreu P et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: results from Trial N9741. Proc Am Soc Clin Oncol 2006; 24: 151 (abstr. 3520).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6500463_CR42","first-page":"263","volume":"23","author":"C Schulz","year":"2005","unstructured":"Schulz C, Schalhorn A, Schwabe W, Haeusler P, Zwingers T, Heinemann V . Impact of gene promoter polymorphism of the UGT1A1-gene on the occurrance of irinotecan-induced side effects and drug effiacy. Proc Am Soc Clin Oncol 2005; 23: 263 (abstr. 3570).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6500463_CR43","first-page":"84","volume":"24","author":"MT Seymour","year":"2006","unstructured":"Seymour MT, Braun MS, Richman SD, Daly C, Thompson LC, Meade A et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer (FOCUS Trial Investigators). Proc Am Soc Clin Oncol 2006; 24: 84 (abstr. 2022).","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6500463_CR44","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1634\/theoncologist.8-5-411","volume":"8","author":"GD Leonard","year":"2003","unstructured":"Leonard GD, Fojo T, Bates SE . The role of ABC transporters in clinical practice. Oncologist 2003; 8: 411\u2013424.","journal-title":"Oncologist"},{"key":"BF6500463_CR45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/10915810600746023","volume":"25","author":"S Choudhuri","year":"2006","unstructured":"Choudhuri S, Klaassen CD . Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25: 231\u2013259.","journal-title":"Int J Toxicol"},{"key":"BF6500463_CR46","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/1078-0432.1226.11.3","volume":"11","author":"LE Carlini","year":"2005","unstructured":"Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine\/irinotecan. Clin Cancer Res 2005; 11: 1226\u20131236.","journal-title":"Clin Cancer Res"},{"key":"BF6500463_CR47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/03602530600739835","volume":"38","author":"S Nagar","year":"2006","unstructured":"Nagar S, Blanchard RL . Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 2006; 38: 393\u2013409.","journal-title":"Drug Metab Rev"},{"key":"BF6500463_CR48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1055-9965.801.13.5","volume":"13","author":"S Savas","year":"2004","unstructured":"Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H . Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004; 13: 801\u2013807.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BF6500463_CR49","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/em.20155","volume":"46","author":"A Kiuru","year":"2005","unstructured":"Kiuru A, Lindholm C, Heilimo I, Ceppi M, Koivistoinen A, Ilus T et al. Influence of DNA repair gene polymorphisms on the yield of chromosomal aberrations. Environ Mol Mutagen 2005; 46: 198\u2013205.","journal-title":"Environ Mol Mutagen"},{"key":"BF6500463_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0921-8777(00)00002-1","volume":"459","author":"MA Brenneman","year":"2000","unstructured":"Brenneman MA, Weiss AE, Nickoloff JA, Chen DJ . XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res 2000; 459: 89\u201397.","journal-title":"Mutat Res"},{"key":"BF6500463_CR51","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1038\/sj.onc.1205539","volume":"21","author":"FD Araujo","year":"2002","unstructured":"Araujo FD, Pierce AJ, Stark JM, Jasim N . Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 2002; 21: 4176\u20134180.","journal-title":"Oncogene"},{"key":"BF6500463_CR52","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1006\/jmbi.2001.4564","volume":"307","author":"C Arnaudeau","year":"2001","unstructured":"Arnaudeau C, Lundin C, Helleday T . DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 2001; 307: 1235\u20131245.","journal-title":"J Mol Biol"},{"key":"BF6500463_CR53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1055-9965.801.13.5","volume":"13","author":"S Savas","year":"2004","unstructured":"Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H . Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004; 13: 801\u2013807.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BF6500463_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctrv.2004.12.006","volume":"31","author":"DM Kweekel","year":"2005","unstructured":"Kweekel DM, Gelderblom H, Guchelaar HJ . Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005; 31: 90\u2013105.","journal-title":"Cancer Treat Rev"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/6500463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500463","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/6500463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:52:58Z","timestamp":1683888778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6500463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,5]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["BF6500463"],"URL":"https:\/\/doi.org\/10.1038\/sj.tpj.6500463","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,5]]},"assertion":[{"value":"19 January 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2007","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2007","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}